Aimmune Therapeutics Inc. (NASDAQ:AIMT)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research note issued to investors on Wednesday. They currently have a $42.00 target price on the stock. Wedbush’s price objective would suggest a potential upside of 165.65% from the company’s current price.

Several other equities analysts have also commented on the company. Credit Suisse Group AG reiterated a “buy” rating and set a $35.00 price objective on shares of Aimmune Therapeutics in a research report on Friday, August 19th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, June 29th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $32.75.

Aimmune Therapeutics (NASDAQ:AIMT) opened at 15.81 on Wednesday. Aimmune Therapeutics has a 52 week low of $9.77 and a 52 week high of $26.50. The firm has a 50-day moving average price of $14.40 and a 200 day moving average price of $13.61. The firm’s market capitalization is $668.04 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/aimmune-therapeutics-inc-aimt-rating-reiterated-by-wedbush.html

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.01. On average, equities research analysts forecast that Aimmune Therapeutics will post ($1.71) earnings per share for the current fiscal year.

In related news, insider Mary M. Rozenman sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total transaction of $504,000.00. Following the transaction, the insider now directly owns 30,000 shares in the company, valued at approximately $504,000. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 24.56% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Aisling Capital LLC raised its position in Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares during the last quarter. TLP Group LLC raised its position in Aimmune Therapeutics by 0.6% in the second quarter. TLP Group LLC now owns 2,833,285 shares of the company’s stock valued at $30,656,000 after buying an additional 17,000 shares during the last quarter. Eagle Asset Management Inc. raised its position in Aimmune Therapeutics by 12.9% in the second quarter. Eagle Asset Management Inc. now owns 1,988,434 shares of the company’s stock valued at $21,514,000 after buying an additional 227,439 shares during the last quarter. Vanguard Group Inc. raised its position in Aimmune Therapeutics by 8.9% in the second quarter. Vanguard Group Inc. now owns 1,339,847 shares of the company’s stock valued at $14,497,000 after buying an additional 109,457 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its position in Aimmune Therapeutics by 798.5% in the second quarter. Pictet Asset Management Ltd. now owns 831,093 shares of the company’s stock valued at $12,757,000 after buying an additional 738,593 shares during the last quarter. Institutional investors and hedge funds own 68.87% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.